|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-20
|
|
pubmed:abstractText |
In type 2 diabetes mellitus (T2DM), oxidative stress gives rise to endothelial dysfunction. Bilirubin, a powerful endogenous antioxidant, significantly attenuates endothelial dysfunction in preclinical experiments. The Gilbert syndrome is accompanied by a mild and lifelong hyperbilirubinemia and associated with only one third of the usual cardiovascular mortality risk. The hyperbilirubinemia caused by atazanavir treatment closely resembles the Gilbert syndrome. We thus hypothesized that treatment with atazanavir would ameliorate oxidative stress and vascular inflammation and improve endothelial function in T2DM.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1524-4636
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
458-63
|
|
pubmed:meshHeading |
pubmed-meshheading:21088253-Acetylcholine,
pubmed-meshheading:21088253-Aged,
pubmed-meshheading:21088253-Bilirubin,
pubmed-meshheading:21088253-Cross-Over Studies,
pubmed-meshheading:21088253-Diabetes Mellitus, Type 2,
pubmed-meshheading:21088253-Double-Blind Method,
pubmed-meshheading:21088253-Endothelium, Vascular,
pubmed-meshheading:21088253-Female,
pubmed-meshheading:21088253-Humans,
pubmed-meshheading:21088253-Male,
pubmed-meshheading:21088253-Middle Aged,
pubmed-meshheading:21088253-Nitroglycerin,
pubmed-meshheading:21088253-Oligopeptides,
pubmed-meshheading:21088253-Oxidative Stress,
pubmed-meshheading:21088253-Pyridines,
pubmed-meshheading:21088253-Vasodilation,
pubmed-meshheading:21088253-Vasodilator Agents,
pubmed-meshheading:21088253-von Willebrand Factor
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus.
|
|
pubmed:affiliation |
Radboud University Nijmegen Medical Centre, Nijimegen Center for Molecular Life Sciences, Departments of Pharmacology and Toxicology, and Orthodontics and Oral Biology, Nijmegen, the Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
